An antibody scanning method for the detection of α-synuclein oligomers in the serum of Parkinson's disease patients

Misfolded α-synuclein oligomers are closely implicated in the pathology of Parkinson's disease and related synucleinopathies. The elusive nature of these aberrant assemblies makes it challenging to develop quantitative methods to detect them and modify their behavior. Existing detection methods use antibodies to bind α-synuclein aggregates in biofluids, although it remains challenging to raise antibodies against α-synuclein oligomers. To address this problem, we used an antibody scanning approach in which we designed a panel of 9 single-domain epitope-specific antibodies against α-synuclein. We screened these antibodies for their ability to inhibit the aggregation process of α-synuclein, finding that they affected the generation of α-synuclein oligomers to different extents. We then used these antibodies to investigate the size distribution and morphology of soluble α-synuclein aggregates in serum and cerebrospinal fluid samples from Parkinson's disease patients. Our results indicate that the approach that we present offers a promising route for the development of antibodies to characterize soluble α-synuclein aggregates in biofluids.

[1]  D. Klenerman,et al.  Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease , 2021, Brain : a journal of neurology.

[2]  M. Vendruscolo,et al.  Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases , 2021, Nature Reviews Chemistry.

[3]  C. Dobson,et al.  Screening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter , 2020, Communications Chemistry.

[4]  S. Stott,et al.  Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020 , 2020, Journal of Parkinson's disease.

[5]  C. Dobson,et al.  Rational design of a conformation-specific antibody for the quantification of Aβ oligomers , 2020, Proceedings of the National Academy of Sciences.

[6]  S. Lesné,et al.  Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk , 2020, Journal of Parkinson's disease.

[7]  Suneil K. Kalia,et al.  Methods for detecting toxic α-synuclein species as a biomarker for Parkinson’s disease , 2020, Critical reviews in clinical laboratory sciences.

[8]  M. Morawski,et al.  Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro , 2020, Molecules.

[9]  D. Klenerman,et al.  Analysis of α-synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies , 2020, Brain communications.

[10]  R. Riek,et al.  Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy , 2019, eLife.

[11]  R. Wade-Martins,et al.  Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease , 2019, Front. Mol. Neurosci..

[12]  Craig D. Hughes,et al.  Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression , 2019, Acta Neuropathologica Communications.

[13]  Michele Vendruscolo,et al.  Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms , 2019, Nature Communications.

[14]  M. Vendruscolo,et al.  Protein Solubility Predictions Using the CamSol Method in the Study of Protein Homeostasis. , 2019, Cold Spring Harbor perspectives in biology.

[15]  Zheyu Xu,et al.  Plasma alpha‐synuclein detected by single molecule array is increased in PD , 2019, Annals of clinical and translational neurology.

[16]  Eyal Oren,et al.  Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, The Lancet. Neurology.

[17]  Michele Vendruscolo,et al.  Third generation antibody discovery methods: in silico rational design. , 2018, Chemical Society reviews.

[18]  D. Eisenberg,et al.  Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel , 2018, Nature Communications.

[19]  C. Dobson,et al.  Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers , 2017, Science.

[20]  Young Ho Park,et al.  Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.

[21]  K. Y. Han,et al.  Endogenous Alpha-Synuclein Protein Analysis from Human Brain Tissues Using Single-Molecule Pull-Down Assay. , 2017, Analytical chemistry.

[22]  Michele Vendruscolo,et al.  Selective targeting of primary and secondary nucleation pathways in Aβ42 aggregation using a rational antibody scanning method , 2017, Science Advances.

[23]  Joseph Jankovic,et al.  Diagnosis and Management of Parkinson's Disease , 2017, Seminars in Neurology.

[24]  Alexander K. Buell,et al.  Mutations associated with familial Parkinson’s disease alter the initiation and amplification steps of α-synuclein aggregation , 2016, Proceedings of the National Academy of Sciences.

[25]  Michele Vendruscolo,et al.  Hamiltonian Dynamics of Protein Filament Formation. , 2016, Physical review letters.

[26]  Takahiko Tokuda,et al.  Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease , 2016, Molecular Neurodegeneration.

[27]  M. Vendruscolo,et al.  Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins , 2015, Proceedings of the National Academy of Sciences.

[28]  Fang-fei Li,et al.  Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease , 2015, Neuroscience Letters.

[29]  C. Dobson,et al.  Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. , 2015, Nature chemical biology.

[30]  Michele Vendruscolo,et al.  The CamSol method of rational design of protein mutants with enhanced solubility. , 2015, Journal of molecular biology.

[31]  S. Cheon,et al.  Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease , 2011, Journal of clinical neurology.

[32]  M. Hingorani.  Faculty Opinions recommendation of Probing cellular protein complexes using single-molecule pull-down. , 2011 .

[33]  R. Nussbaum,et al.  Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein α-Synuclein*♦ , 2011, The Journal of Biological Chemistry.

[34]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[35]  Ronald M. Levy,et al.  Structural Reorganization of α-Synuclein at Low pH Observed by NMR and REMD Simulations , 2009 .

[36]  W Poewe,et al.  Diagnosis and management of Parkinson's disease dementia , 2008, International journal of clinical practice.

[37]  N. Avadhani,et al.  Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.

[38]  C. Dobson,et al.  Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. , 2005, Journal of the American Chemical Society.

[39]  Dong Joon Kim,et al.  A rapid, simple measurement of human albumin in whole blood using a fluorescence immunoassay (I). , 2004, Clinica chimica acta; international journal of clinical chemistry.

[40]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[41]  E. Masliah,et al.  α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .